Updated May 30, 2026, 4:23 PM
Androgenic anabolic steroidUS FDA Database Verified

testosterone (Rx)

Generic: Testosterone

Brand: multiple, see below

(tess-toss'te-rone)

Pregnancy Category: X
Controlled substance schedule III

Pharmacological Action

Increases weight by building body tissue; increases potassium, phosphorus, chloride, nitrogen levels; increases bone development; responsible for maintenance of secondary sex characteristics (male)

Therapeutic outcome: Increased hormone levels in eunuchoidism, decreased tumor growth in female breast cancer, onset of male puberty

Uses

Female breast cancer, hypogonadism, eunuchoidism, male climacteric, oligospermia, impotence, vulvar dystrophies, low testosterone levels, delayed male puberty (inj)

Contraindications

Pregnancy X, breastfeeding, severe renal/cardiac/hepatic disease, hypersensitivity, genital bleeding (rare), male breast/prostate cancer

Precautions: Diabetes mellitus, CV disease, MI, urinary tract disorders, prostate cancer, hypercalcemia

BLACK BOX WARNING: Children, accidental exposure

Dosage & Routes

Replacement

Adult: IM (enanthate or cypionate) 50-400 mg q2-4 wk; transdermal (Testoderm) 4-6 mg applied q24 hr; (Androderm, AndroGel) 5 mg applied q24 hr; once daily (gel); topical sol (Axiron) 60 mg (2 pump activations) each am; BUCCAL 1 buccal system (30 mg) to the gum region q12 hr before meals/pm Adult (male) and child: SUBCUT (pellets) 150-450 mg (2-6 pellets) inserted q3-6 mo Breast cancer

Adult: IM 50-100 mg 3 3/wk (propionate) or 200-400 mg q2-4 wk (cypionate or enanthate) Delayed male puberty Child >12 yr: IM up to 100 mg/mo for up to 6 mo

Available forms:

Enanthate: inj 200 mg/ml; cypionate: inj 100, 200 mg/ml; pellets 75 mg; transdermal 2, 4 mg/24 hr; gel 1%, 1.62%, 10 mg/actuation; buccal system 30 mg; topical solution 30 mg/actuation

Implementation - Administer diet with increased calories, protein; decreased sodium if edema occurs - Administer supportive product if anemia occurs - Give titrated dose; use lowest effective dose - Give IM inj deep into upper outer quadrant of gluteal muscle; route can be painful Transdermal route - Apply Testoderm to skin of scrotum, Androderm to skin of back, upper arms, thighs, abdomen; area must be clean and dry, free of hair Gel route - Products are not interchangeable, dosage and administration for AndroGel 1% differs from AndroGel 1.62% - Apply daily to clean dry area on shoulders, upper arms, or abdomen; women, children should not touch gel or treated skin Buccal system route - Do not chew or swallow buccal system - Rotate sites; place above incisor tooth on either side of mouth - Open packet; place rounded side of surface against gum and hold firmly in place with finger over lip for 30 sec; if product falls off, replace with new system; discard in trash can away from children or pets Topical solution - Using the provided applicator, apply the solution to clean, dry, intact skin of the axilla, preferably at the same time each morning. Do not apply to any other part of the body. Allow the solution to dry completely before dressing. If an antiperspirant or deodorant is used, apply at least 2 min before applying the solution. The pump must be primed before the first use by fully depressing the pump mechanism 3 times and discarding any solution that is released during the priming. To dispense the solution, position the nozzle over the applicator cup and carefully depress the pump once fully; the cup should be filled with no more than 1 pump actuation (30 mg). With the applicator upright, place it up into the axilla and wipe steadily down and up into the axilla. Do not use fingers or hand to rub the solution. If multiple applications are necessary for the required dose, alternate application between the left and right axilla. When repeat application to the same axilla is necessary, allow the solution to dry completely before the next application. After use, rinse the applicator under running water and pat dry with tissue. Wash hands with soap and water - Following application, allow the site to dry a few minutes before putting on clothing - Direct contact of the medicated skin with the skin of another person can result in the transfer of residual testosterone and absorption by the other person. To reduce accidental transfer, the patient should cover the application site(s) with clothing (e.g., a T-shirt) after the solution has dried. The application site should be washed with soap and water prior to any skin-to-skin contact regardless of the length of time since application. In the case of direct contact, the other person should wash the area of contact with soap and water as soon as possible - Patients should be advised that the topical solution is flammable; therefore, fire, flame, and smoking should be avoided during use - Advise patients to avoid swimming or washing the application site until 2 hr following application of solution

Adverse Effects

CNS: Dizziness, headache, fatigue, tremors, paresthesias, flushing, sweating, anxiety, lability, insomnia, carpal tunnel syndrome

CV: Increased B/P

EENT: Conjunctival edema, nasal congestion

ENDO: Abnormal GTT

GI: Nausea, vomiting, constipation, weight gain, cholestatic jaundice

GU: Hematuria, amenorrhea, vaginitis, decreased libido, decreased breast size, clitoral hypertrophy, testicular atrophy, gynecomastia, enlarged prostate

HEMA: Polycythemia

INTEG: Rash, acneiform lesions, oily hair and skin, flushing, sweating, acne vulgaris, alopecia, hirsutism

MS: Cramps, spasms

Pharmacokinetics

Absorption: Well but slowly absorbed

Distribution: Crosses placenta

Metabolism: Liver

Excretion: Kidneys, breast milk

Half-life: 8 days (cypionate); 10-100 min (base)

Pharmacodynamics

IM (base): Onset Unknown, Peak Unknown, Duration 1-3 days IM (cypionate): Onset Unknown, Peak Unknown, Duration 2-4 wk IM (enanthate): Onset Unknown, Peak Unknown, Duration 2-4 wk IM (propionate): Onset Unknown, Peak Unknown, Duration 1-3 days

Interactions

Individual drugs ACTH, buPROPion: increased edema

Insulin: decreased glucose levels may alter need for insulin

Oxyphenbutazone: increased effects of oxyphenbutazone

Drug classifications Adrenal steroids: increased edema

Anticoagulants: increased pro-time Antidiabetics, oral: decreased need for oral antidiabetics

Drug/lab test

Increased: serum cholesterol, blood glucose, urine glucose

Decreased: serum Ca, serum K, T4, T3, thyroid 131 I uptake test, urine 17-OHCS, 17-KS, PBI

Nursing Considerations

Assessment - Monitor patient's weight daily; notify prescriber if weekly weight gain is >5 lb; assess • I&O ratio; be alert for decreasing urinary output, increasing edema - Monitor B/P q4 hr, Hgb/Hct - Assess growth rate, bone age in adolescent because growth rate may be uneven (linear/bone growth) if used for extended periods - Monitor electrolytes: potassium, sodium, chloride, calcium; cholesterol - Monitor liver function tests: ALT, AST, bilirubin - Assess edema, hypertension, cardiac symptoms, jaundice - Assess mental status: affect, mood, behavioral changes, aggression - Assess signs of masculinization in female: increased libido, deepening of voice, decreased breast tissue, enlarged clitoris, menstrual irregularities; male: gynecomastia, impotence, testicular atrophy - Assess hypercalcemia: lethargy, polyuria, polydipsia, nausea, vomiting, constipation; product may have to be decreased - Assess hypoglycemia in diabetics because oral antidiabetic action is increased

Patient/family education - Inform patient that product needs to be combined with complete health plan: diet, rest, exercise - Caution patient to notify prescriber if therapeutic response decreases; not to discontinue this medication abruptly - Inform women patients to report menstrual irregularities; about changes in sex characteristics - Discuss that 1-3 mo course is necessary for response in breast cancer - Inform patient about application of transdermal patches: Testoderm to skin of scrotum, Androderm to skin of back, upper arms, thighs, abdomen; area must be dry and free of hair; may be reapplied after bathing, swimming - Teach about changes in sex characteristics: priapism, gynecomastia, increased libido

Evaluation

Positive therapeutic outcome: Decrease size of tumor in breast cancer; Increased androgen levels

Reference

Mosby's Drug Guide; Davis Drug Guide

Need clinical tools for this drug?

Save notes, bookmark this drug, and run formula method (desire over have) dosage calculations all inside the KosPharm Dashboard.

One-time payment. No subscription. No recurring charges.

Sign in to Get Full Access